Pharmaceutical Litigation
Bextra®
Manufacturer:
Pfizer
Uses: Bextra (valdecoxib tablets) is a powerful medicine for the joint pain of osteoarthritis and adult rheumatoid arthritis, and painful menstrual cramps.
More Information
FDA Alert
After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested
that Pfizer, Inc. voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on:
- The lack of adequate data on the cardiovascular safety of long-term use of Bextra, along with the increased risk of adverse cardiovascular (CV) events in short-term coronary artery bypass surgery (CABG) trials that
the FDA believes may be relevant to chronic use.
- Reports of serious and potentially life-threatening skin reactions, including deaths, in patients using Bextra. The risk of these reactions in individual patients is unpredictable, occurring in patients with and without a prior history of sulfa allergy, and after both short- and long-term use.
- Lack of any demonstrated advantages for Bextra compared with other NSAIDs.
Patients currently taking Bextra should contact their physicians to consider alternative treatments.
The FDA is also asking manufacturers of all marketed prescription NSAIDs, including Celebrex (celecoxib), a COX-2 selective NSAID, to revise the labeling (package insert) for their products to include a boxed warning and a Medication Guide. The boxed warning will highlight the potential for increased risk of CV events with these drugs and the well-described, serious, and potentially life-threatening gastrointestinal (GI) bleeding associated with their use. The Medication Guide will accompany every prescription NSAID at the time it is dispensed to better inform patients about the CV and GI risks. Finally,
the FDA is asking manufacturers of non-prescription (OTC) NSAIDs to revise their labeling to include more specific information about the potential GI and CV risks, and information to assist consumers in the safe use of the drug. This announcement does not apply to aspirin as it has clearly been shown to reduce the risk of serious adverse CV events in certain patient populations.
 |
| Bextra |
On December 10th, 2004 the FDA announced important new information on side effects associated with the use of Bextra, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of osteoarthritis, rheumatoid arthritis and dysmenorrhea (menstrual pain). A "boxed" warning, strengthening previous warnings about the risk of life-threatening skin reactions, and a new bolded warning contraindicating the use of Bextra in patients undergoing coronary artery bypass graft (CABG) surgery were added to the label.
Side Effects
- Higher incidence of heart attack, stroke, and clotting in the veins and lungs
- Life-threatening skin reactions
Featured Articles
For more information:
Pharmaceutical Litigation
Prescription
Injury FAQs
Pharmaceutical Legal Glossary
Disclaimer
Bextra Attorneys Disclaimer: The Bextra,
arthritis drug, prescription drug injury, pharmaceutical litigation or other
personal injury legal information presented at this site should not be
construed to be formal legal advice, nor the formation of a lawyer or
attorney-client relationship. Any results set forth herein are based upon
the facts of that particular case and do not represent a promise or
guarantee. Please contact a Bextra attorney or prescription drug injury
lawyer for a consultation on your particular personal injury matter. This
web site is not intended to solicit clients for matters outside the states
of Missouri and Kansas.
|
